The clinical performance is complex and often involves multiple systems. Early identification and normalisation of the diagnosis are essential for improving the prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological evaluation.
The platform can assist in connecting a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment to changes in the course of the disease.
Multidisciplinary collaboration (MDT) is especially important for the integrated management of HL pregnancy. The platform serves China International Medical Service System, a team of domestically and abroad authoritative experts in the field of blood tumours, who provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.